[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367735-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367735-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-pan-cancer-analysis-of-natriuretic-peptide-receptor-3-npr3-original-research-clinical-cohort-and-in-vitro-validation","A Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) - Original Research - Clinical Cohort and in vitro Validation","","Pan-cancer roles of natriuretic peptide receptor 3 (NPR3) remain insufficiently defined despite its regulatory functions in angiogenesis, immune modulation, and cancer progression. This study integrates analyses across 20 public databases to evaluate NPR3 differential expression, ceRNA and PPI networks, survival associations, tumor purity and genomics, immunity, drug sensitivity, molecular docking, and signaling pathways. In a clinical cohort of 370 kidney-neoplasm patients, immunohistochemistry distinguishes tumor versus normal expression and supports prognostic stratification. Cell experiments further test functional effects in renal cancer cell lines.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-pan-cancer-analysis-of-natriuretic-peptide-receptor-3-npr3-original-research-clinical-cohort-and-in-vitro-validation/367735/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-pan-cancer-analysis-of-natriuretic-peptide-receptor-3-npr3-original-research-clinical-cohort-and-in-vitro-validation/367735.png","ImageObject",300,407,{"name":42,"@type":43},"eBook King","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study on NPR3?","Question",{"text":63,"@type":64},"To comprehensively characterize NPR3’s role across multiple cancers, with emphasis on whether it can serve as a prognostic biomarker, especially in kidney cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which kinds of analyses are performed in the pan-cancer component?",{"text":68,"@type":64},"The study evaluates differential expression, ceRNA and PPI networks, Kaplan–Meier survival, correlations with clinical and molecular features, tumor immunity, drug sensitivity, molecular docking, and signaling pathways using 20 datasets.",{"name":70,"@type":61,"acceptedAnswer":71},"How was NPR3 expression validated in kidney neoplasms?",{"text":72,"@type":64},"A cohort of 370 kidney-neoplasm patients was analyzed with immunohistochemistry to compare tumor and normal tissues, determine an IHC cutoff using the surv_cutpoint function, and run survival analyses; external datasets were used for further validation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367735,1790443900,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Journal of Inflammation Research  \n Open Access Full Text Article  \nORIGINAL RESEARCH  \nA Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) with Clinical Cohort and in vitro Validation  \nYifan Liu 1 , *, Jiangui Liu 1 , *, Yuanan Li 1 , *, Zihui Zhao 1 , *, Donghao Lyu 1 , Keqin Dong 1 , Maodong Wei 1 , Runzhi Huang2 , Bingnan Lu 1 , Xiuwu Pan 1  \n1Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, People’s Republic of China; 2Department of Burn Surgery, the First Affiliated Hospital of Naval Medical University, Shanghai, 200433, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Xiuwu Pan; Bingnan Lu, Department of Urology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, No. 1665 Kongjiang Road, Shanghai, 200092, People’s Republic of China, [Email panxiuwu@126.com](Email panxiuwu@126.com); [972081060@qq.com](972081060@qq.com)  \n\n| Background: Natriuretic peptide receptor 3 (NPR3) regulates natriuretic peptides and plays a key role in angiogenesis, immune regulation, and progression of certain cancers. However, the clinical significance of NPR3 at pan-cancer level remains poorly understood. This study aimed to comprehensively analyze NPR3’s role across multiple cancers, focusing on its potential asa prognostic biomarker, particularly in kidney cancer.\u003Cbr>Methods: A comprehensive pan-cancer study of NPR3 was conducted using 20 different databases and datasets. The study included differential expression analysis, competing endogenous RNA (ceRNA) analysis, protein–protein interaction (PPI) analysis, Kaplan– Meier (K-M) survival analysis, and correlation assessments of NPR3 with clinical characteristics, tumor purity, tumor genomics, tumor immunity, drug sensitivity, molecular docking, and signaling pathways. Additionally, using a cohort of 370 patients diagnosed with kidney neoplasms, immunohistochemistry (IHC) was employed to assess NPR3 expression differences between tumor and normal tissues. The IHC cutoff point was determined using the “surv_cutpoint” function, followed by survival analysis. Multiple external datasets were used to validate the results. Cell-based experiments in 786-O, 769-P, and A-498 cell lines were further conducted. Results: In pan-cancer, NPR3 was down-regulated in most of the tumor types, and ceRNA and PPI network were constructed. Moreover, NPR3 expression was significantly associated with the clinical prognosis and stages, tumor purity, genetic mutation, immune infiltration and signaling pathways and drug sensitivity. In kidney neoplasm, NPR3 was down-regulated, and higher expression was associated with a better prognosis. Multivariate Cox regression analysis showed that NPR3 expression was protective factor for both OS (HR = 0.50, 95% CI = 0.29–0.87, p = 0.013) and PFS (HR = 0.66, 95% CI = 0.46–0.95, p = 0.024) . In renal cancer cells, NPR3-knockdown significantly suppressed tumor proliferative and migration activity.\u003Cbr>Conclusion: NPR3 servers as a prognostic and immunotherapeutic biomarker in pan-cancer, but its biological role and potential asa therapeutic target warrants further investigation.\u003Cbr>Keywords: NPR3, pan-cancer, kidney cancer |\n| --- |\n| Introduction\u003Cbr>Cancer has become a major global public health concern, imposing substantial socioeconomic burdens. In 2024, an estimated 2,001,140 new cancer cases occurred in the United States alone.1 Despite the large number of patients requiring effective treatment, traditional therapies often fall short due to limited tumor specificity. Recently, tumor immunotherapy has shown great promise as a novel treatment approach.2,3 However, the success of immunotherapy relies heavily on the identification of specific tumor biomarkers, which remain scarce for many cancer types.4–6 Therefore, the discovery of novel biomarkers is essential for advancing precision oncology. |\n\nReceived: 23 January 2025  \n","cbCaibVOsSgjAlWk","https://ap.wps.com/l/cbCaibVOsSgjAlWk","pdf",20039988,25,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Introduction","[{\"question\":\"What is the main objective of the study on NPR3?\",\"answer\":\"To comprehensively characterize NPR3’s role across multiple cancers, with emphasis on whether it can serve as a prognostic biomarker, especially in kidney cancer.\"},{\"question\":\"Which kinds of analyses are performed in the pan-cancer component?\",\"answer\":\"The study evaluates differential expression, ceRNA and PPI networks, Kaplan–Meier survival, correlations with clinical and molecular features, tumor immunity, drug sensitivity, molecular docking, and signaling pathways using 20 datasets.\"},{\"question\":\"How was NPR3 expression validated in kidney neoplasms?\",\"answer\":\"A cohort of 370 kidney-neoplasm patients was analyzed with immunohistochemistry to compare tumor and normal tissues, determine an IHC cutoff using the surv_cutpoint function, and run survival analyses; external datasets were used for further validation.\"}]","A Pan-Cancer Analysis of Natriuretic Peptide Receptor 3 (NPR3) - Original Research - Clinical Cohort and in vitro Validation | PDF",1790172311,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d541e32ab240ab65a82c1ae48d86252f.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85c2655b93e99c9465bb37daecc0b90e.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c043747f014efb59ef2f7c60ee874aae.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63fa22053cfc4dd291fa0080e625ef78.webp",980,1268]